ECSP10010415A - Compuestos novedosos que son inhibidores de erk - Google Patents

Compuestos novedosos que son inhibidores de erk

Info

Publication number
ECSP10010415A
ECSP10010415A EC2010010415A ECSP10010415A ECSP10010415A EC SP10010415 A ECSP10010415 A EC SP10010415A EC 2010010415 A EC2010010415 A EC 2010010415A EC SP10010415 A ECSP10010415 A EC SP10010415A EC SP10010415 A ECSP10010415 A EC SP10010415A
Authority
EC
Ecuador
Prior art keywords
erk inhibitors
new compounds
formula
compounds
erk
Prior art date
Application number
EC2010010415A
Other languages
English (en)
Spanish (es)
Inventor
Neng Yang Shih
Sunil Paliwal
Hon-Chung Tsui
Alan B Cooper
Jagdish A Desai
Ronald J Doll
Hugh Y Zhu
Gerald W Shipps Jr
James J S Wang
Yongqi Deng
Yang Nan
Sobhana Babu Boga
Abdul-Basit Alhassan
Xiaolei Gao
Liang Zhu
Mehul Patel
Subrahmanyam Gudipati
Xin Yao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010415(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP10010415A publication Critical patent/ECSP10010415A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EC2010010415A 2008-02-21 2010-08-20 Compuestos novedosos que son inhibidores de erk ECSP10010415A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21

Publications (1)

Publication Number Publication Date
ECSP10010415A true ECSP10010415A (es) 2010-09-30

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010415A ECSP10010415A (es) 2008-02-21 2010-08-20 Compuestos novedosos que son inhibidores de erk

Country Status (23)

Country Link
US (1) US8716483B2 (enExample)
EP (1) EP2260031B1 (enExample)
JP (1) JP5276676B2 (enExample)
KR (1) KR20100117123A (enExample)
CN (1) CN102015693B (enExample)
AR (1) AR070460A1 (enExample)
AU (1) AU2009215534B8 (enExample)
BR (1) BRPI0908120A8 (enExample)
CA (1) CA2714479A1 (enExample)
CL (1) CL2009000394A1 (enExample)
CO (1) CO6300939A2 (enExample)
EC (1) ECSP10010415A (enExample)
ES (1) ES2556353T3 (enExample)
IL (1) IL207530A (enExample)
MX (1) MX2010009268A (enExample)
MY (1) MY152271A (enExample)
NZ (1) NZ587504A (enExample)
PE (1) PE20091491A1 (enExample)
RU (1) RU2525389C2 (enExample)
SG (1) SG188179A1 (enExample)
TW (1) TWI398441B (enExample)
WO (1) WO2009105500A1 (enExample)
ZA (2) ZA201005909B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
CN101415674A (zh) 2006-02-16 2009-04-22 先灵公司 作为erk抑制剂的吡咯烷衍生物
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
WO2010021978A2 (en) * 2008-08-19 2010-02-25 Schering Corporation Il-8 biomarker
WO2011002887A1 (en) 2009-07-02 2011-01-06 Schering Corporation FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物
US8999957B2 (en) * 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
WO2012036997A1 (en) * 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
CN103270029B (zh) 2010-10-22 2016-01-20 拜耳知识产权有限责任公司 作为农药的杂环化合物
CA2818561A1 (en) * 2010-11-16 2012-05-24 Medimmune, Llc Regimens for treatments using anti-igf antibodies
WO2013015918A1 (en) 2011-07-22 2013-01-31 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
CA2866086C (en) 2012-03-01 2020-06-09 Genentech, Inc. Serine/threonine kinase inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
WO2014012360A1 (en) 2012-07-18 2014-01-23 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
EP2900223B1 (en) * 2012-09-28 2017-10-25 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN105050598B (zh) * 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
NZ711192A (en) * 2013-03-13 2019-04-26 Hoffmann La Roche Process for making benzoxazepin compounds
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
KR20160081908A (ko) 2013-10-03 2016-07-08 쿠라 온콜로지, 인크. Erk의 억제제 및 사용 방법
US10428387B2 (en) 2014-05-16 2019-10-01 University Of Massachusetts Treating chronic myelogenous leukemia (CML)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
JP6657223B2 (ja) 2014-12-18 2020-03-04 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 医薬調製物用の（ｓ）−ｎ−（３−（６−イソプロポキシピリジン−３−イル）−１ｈ−インダゾール−５−イル）−１−（２−（４−（４−（１−メチル−１ｈ−１，２，４−トリアゾール−３−イル）フェニル）−３，６−ジヒドロピリジン−１（２ｈ）−イル）−２−オキソエチル）−３−（メチルチオ）ピロリジン−３−カルボキサミド組成物
WO2016100152A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
CA2981055A1 (en) * 2015-04-03 2016-10-06 Kalyra Pharmaceuticals, Inc. Spirocyclic compounds
WO2017040362A1 (en) * 2015-09-03 2017-03-09 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
EP4041393A1 (en) 2019-10-09 2022-08-17 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
CA3160899C (en) 2019-12-06 2024-04-16 Medshine Discovery Inc. Spiro compound serving as erk inhibitor, and application thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
AU3215197A (en) 1996-05-30 1998-01-05 Merck & Co., Inc. A method of treating cancer
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
ES2339196T3 (es) 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
CZ20013540A3 (cs) 2000-02-05 2002-03-13 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu jako inhibitory ERK a farmaceutický prostředek, který je obsahuje
CA2369502A1 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
DE60128709T2 (de) 2000-09-15 2007-12-27 Vertex Pharmaceuticals Inc., Cambridge Triazol-verbindungen als protein-kinase-inhibitoren
EP1317453B1 (en) 2000-09-15 2006-08-09 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
US6696443B2 (en) * 2000-11-20 2004-02-24 Scios, Inc. Piperidine/piperazine-type inhibitors of p38 kinase
MXPA03005608A (es) * 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
KR20040007497A (ko) * 2001-04-16 2004-01-24 에자이 가부시키가이샤 신규 1ｈ-인다졸 화합물
AU2002305260A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
JP2004532234A (ja) 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
MXPA04001087A (es) 2001-08-03 2004-07-08 Vertex Pharma Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
DE60238620D1 (de) 2001-08-03 2011-01-27 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
EP2332922A1 (en) 2001-10-23 2011-06-15 Merck Serono S.A. N-substituted azoles and their use as MEK-1 and/or ERK-2 modulators
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003237121A1 (en) 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
WO2003099212A2 (en) 2002-05-24 2003-12-04 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
CN1656079A (zh) * 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004026867A2 (en) 2002-09-19 2004-04-01 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
US7456190B2 (en) 2003-03-13 2008-11-25 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050107386A1 (en) * 2003-11-19 2005-05-19 Rama Krishna Narla Methods of treating diseases and disorders by targeting multiple kinases
AU2004308974A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
WO2005100342A1 (en) 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
JP2007532615A (ja) 2004-04-13 2007-11-15 アステックス、セラピューティックス、リミテッド 医薬化合物
RU2006144448A (ru) 2004-05-14 2008-06-20 Вертекс Фармасьютикалз Пролекарства пирролилпиримидиновых ингибиторов протеинкиназы erk
AU2005245885B2 (en) 2004-05-14 2011-01-20 Vertex Pharmaceuticals, Incorporated Pyrrole compounds as inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
WO2006071644A1 (en) 2004-12-23 2006-07-06 Vertex Pharmaceuticals Incorporated Selective inhibitors of erk protein kinases and uses therof
CN100377868C (zh) * 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) * 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
DK1966151T3 (da) * 2005-12-13 2012-01-30 Schering Corp Polycykliske indazolderivater, der er ERK-hæmmere
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
CN101415674A (zh) * 2006-02-16 2009-04-22 先灵公司 作为erk抑制剂的吡咯烷衍生物
WO2007123186A1 (ja) * 2006-04-20 2007-11-01 Takeda Pharmaceutical Company Limited 医薬
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
JP2009542666A (ja) * 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増加させる置換ピペリジンおよびその使用
US7671832B2 (en) * 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
CN101674834B (zh) 2007-03-28 2013-06-12 环状药物公司 布鲁顿氏酪氨酸激酶(Bruton's tyrosine kinase)抑制剂
TW200911262A (en) * 2007-06-05 2009-03-16 Schering Corp Novel compounds that are ERK inhibitors
SG182187A1 (en) 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors
JP2010530421A (ja) 2007-06-18 2010-09-09 シェーリング コーポレイション 複素環化合物およびｅｒｋ阻害剤としてのそれらの使用
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物

Also Published As

Publication number Publication date
CL2009000394A1 (es) 2011-02-11
ES2556353T3 (es) 2016-01-15
RU2010138635A (ru) 2012-03-27
CO6300939A2 (es) 2011-07-21
AU2009215534A8 (en) 2014-07-10
MY152271A (en) 2014-09-15
RU2525389C2 (ru) 2014-08-10
TWI398441B (zh) 2013-06-11
SG188179A1 (en) 2013-03-28
ZA201005909B (en) 2014-03-26
ZA201400396B (en) 2014-12-23
JP2011513225A (ja) 2011-04-28
KR20100117123A (ko) 2010-11-02
AU2009215534B8 (en) 2014-07-10
AU2009215534B2 (en) 2014-06-26
CN102015693A (zh) 2011-04-13
AU2009215534A1 (en) 2009-08-27
AU2009215534A2 (en) 2010-12-23
BRPI0908120A8 (pt) 2017-10-24
WO2009105500A1 (en) 2009-08-27
ES2556353T8 (es) 2017-10-13
IL207530A0 (en) 2010-12-30
BRPI0908120A2 (enExample) 2017-08-22
US20110189192A1 (en) 2011-08-04
EP2260031A1 (en) 2010-12-15
IL207530A (en) 2014-08-31
TW200948799A (en) 2009-12-01
JP5276676B2 (ja) 2013-08-28
AR070460A1 (es) 2010-04-07
NZ587504A (en) 2012-09-28
MX2010009268A (es) 2010-09-14
EP2260031B1 (en) 2015-10-07
PE20091491A1 (es) 2009-09-25
CA2714479A1 (en) 2009-08-27
US8716483B2 (en) 2014-05-06
CN102015693B (zh) 2014-10-29

Similar Documents

Publication Publication Date Title
ECSP10010415A (es) Compuestos novedosos que son inhibidores de erk
UY31774A (es) Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
NI201900077A (es) Inhibidores selectivos de jak1
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
ECSP11011439A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
NI201200132A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos
MX2015011311A (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos del mismo como inhibidores de atotaxina.
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY31524A1 (es) Nuevos compuestos 010
ECSP099781A (es) Novedosos compuestos que son inhibidores de erk
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
UY32049A (es) Inhibidores de cmet
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
DOP2009000242A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer
UY30912A1 (es) Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso.
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
MX2018008772A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
CL2023002486A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
UY29804A1 (es) Quinolinas de alquilnitrilo
ECSP13012372A (es) Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.